Adaptive Biotechnologies (FRA:1HM) ROCE % : -32.14% (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Adaptive Biotechnologies ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Adaptive Biotechnologies's annualized ROCE % for the quarter that ended in Mar. 2024 was -32.14%.

Adaptive Biotechnologies ROCE % Historical Data

The historical data trend for Adaptive Biotechnologies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adaptive Biotechnologies ROCE % Chart

Adaptive Biotechnologies Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-13.79

-15.88

-23.71

-26.05

-31.52

Adaptive Biotechnologies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-29.76	-25.65	-29.09	-43.90	-32.14

Adaptive Biotechnologies ROCE % Calculation

Adaptive Biotechnologies's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-193.949	/	( ( (808.646 - 103.64)	+	(606.26 - 80.71) )	/ 2 )
	=	-193.949	/	( (705.006	+	525.55)	/ 2 )
	=	-193.949	/	615.278
	=	-31.52 %

Adaptive Biotechnologies's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-163.908	/	( ( (606.26 - 80.71)	+	(570.697 - 76.316) )	/ 2 )
	=	-163.908	/	( ( 525.55	+	494.381 )	/ 2 )
	=	-163.908	/	509.9655
	=	-32.14 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Adaptive Biotechnologies (FRA:1HM) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Adaptive Biotechnologies ROCE % Related Terms

Thank you for viewing the detailed overview of Adaptive Biotechnologies's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Adaptive Biotechnologies (FRA:1HM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptive Biotechnologies Corp (FRA:1HM) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ADPT:USA

Address

1165 Eastlake Avenue East, Seattle, WA, USA, 98109

Website

https://www.adaptivebiotech.com

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease ("MRD") in patients with multiple myeloma ("MM"), B cell acute lymphoblastic leukemia ("ALL") and chronic lymphocytic leukemia ("CLL") and is also available as a CLIA-validated laboratory developed test ("LDT") for patients with other lymphoid cancers, including diffuse large B-cell lymphoma ("DLBCL").

Adaptive Biotechnologies (FRA:1HM) Headlines

No Headlines